How Small Biotechs Should Protect Their Interests During Mergers and Acquisitions - Early-stage companies need to assess whether a potential deal might unduly encumber the value of their intellectual

ADVERTISEMENT

How Small Biotechs Should Protect Their Interests During Mergers and Acquisitions
Early-stage companies need to assess whether a potential deal might unduly encumber the value of their intellectual property


BioPharm International
Volume 21, Issue 1

Q: How can a company best navigate the complexities of all the tactical options—strategic partnering, collaborations, licensing, another financing round and M&A?

A: Clearly understanding the financial risks and benefits of all options is the first step. However, other factors must be considered—how much control is the company willing to cede? What decision-making responsibilities are most important to the company and the long-term success of the drug or technology? What areas of expertise does the company have and where is it lacking?

Today's deal-making environment offers many options for life sciences companies. Companies need to fully understand the options—and the risks and rewards—related to strategic alliances and M&A so they can make the best decisions to preserve long-term enterprise value and also to enhance the probability of success.

Sergio Garcia is co chair of the life sciences group, and partner, corporate and intellectual property group, at Fenwick & West LLP, San Francisco, CA, 415.875.2366,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here